While in patients dual treatment yielded a 64% response rate and a median PFS of 10.9 months in BRAF V600 mutation-positive NSCLC, combined RAF/MEK treatment in the class I BRAF-mutant melanoma cell line (WM793) displayed additive to antagonistic effects. Here, BRAF is linked to non-small cell lung carcinoma.